TY - JOUR
T1 - Intravitreal pegaptanib sodium (Macugen®) for treatment of diabetic macular oedema
T2 - A morphologic and functional study
AU - Rinaldi, Michele
AU - Chiosi, Flavia
AU - dell'Omo, Roberto
AU - Romano, Mario R.
AU - Parmeggiani, Francesco
AU - Semeraro, Francesco
AU - Mastropasqua, Rodolfo
AU - Costagliola, Ciro
PY - 2012/12
Y1 - 2012/12
N2 - AIMS To study whether morphologic (foveal thickness, FT) variations of clinically significant macular oedema (CMO) in patients suffering from diabetes following intravitreal pegaptanib sodium (IVP) injection were associated with functional [macular sensitivity (MS) and colour discrimination (CD)] changes. METHODS A longitudinal, interventional, non-randomized study was performed. FT was assessed by optical coherence tomography (OCT), MS by microperimetry, best-corrected visual acuity (BCVA) by early treatment diabetic retinopathy study charts (ETDRS) and CD by Farnswoth-Munsell test. The treatment protocol consisted of three consecutive injections (0.3mg/0.05ml; baseline, week 6 and week 12). Follow-up checks were scheduled at 18, 24, 36 and 48 weeks, after injections. RESULTS Thirty eyes of 30 patients with clinically significant CMO were included for analysis. After IVP a significant decrease of FT occurred with a mean reduction from baseline of 56.9% (P= 0.0001). An improvement of functional parameters was recorded in all patients (BCVA from 18.2 ± 8.5 letters to 25.5 ± 8.4 letters, P <0.005, MS from 8.6 ± 2.16 dB to 10.6 ± 2.61 dB, P <0.001, colour analysis from 376.1 ± 125.6 TES to 116 ± 34.6 TES, P= 0.0001). A statistically significant correlation between FT and BCVA as well as MS and CD was also found. Neither ocular nor systemic adverse events were reported. CONCLUSIONS Intravitreal pegaptanib significantly reduced FT, with a concomitant improvement of MS and CD. This association emphasizes the efficacy of IVP in the treatment of CMO.
AB - AIMS To study whether morphologic (foveal thickness, FT) variations of clinically significant macular oedema (CMO) in patients suffering from diabetes following intravitreal pegaptanib sodium (IVP) injection were associated with functional [macular sensitivity (MS) and colour discrimination (CD)] changes. METHODS A longitudinal, interventional, non-randomized study was performed. FT was assessed by optical coherence tomography (OCT), MS by microperimetry, best-corrected visual acuity (BCVA) by early treatment diabetic retinopathy study charts (ETDRS) and CD by Farnswoth-Munsell test. The treatment protocol consisted of three consecutive injections (0.3mg/0.05ml; baseline, week 6 and week 12). Follow-up checks were scheduled at 18, 24, 36 and 48 weeks, after injections. RESULTS Thirty eyes of 30 patients with clinically significant CMO were included for analysis. After IVP a significant decrease of FT occurred with a mean reduction from baseline of 56.9% (P= 0.0001). An improvement of functional parameters was recorded in all patients (BCVA from 18.2 ± 8.5 letters to 25.5 ± 8.4 letters, P <0.005, MS from 8.6 ± 2.16 dB to 10.6 ± 2.61 dB, P <0.001, colour analysis from 376.1 ± 125.6 TES to 116 ± 34.6 TES, P= 0.0001). A statistically significant correlation between FT and BCVA as well as MS and CD was also found. Neither ocular nor systemic adverse events were reported. CONCLUSIONS Intravitreal pegaptanib significantly reduced FT, with a concomitant improvement of MS and CD. This association emphasizes the efficacy of IVP in the treatment of CMO.
KW - Colour test
KW - Diabetic macular oedema
KW - Microperimetry
KW - Pegaptanib
UR - http://www.scopus.com/inward/record.url?scp=84869027076&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84869027076&partnerID=8YFLogxK
U2 - 10.1111/j.1365-2125.2012.04291.x
DO - 10.1111/j.1365-2125.2012.04291.x
M3 - Article
C2 - 22486651
AN - SCOPUS:84869027076
VL - 74
SP - 940
EP - 946
JO - British Journal of Clinical Pharmacology
JF - British Journal of Clinical Pharmacology
SN - 0306-5251
IS - 6
ER -